Navigation Links
Saladax Biomedical, Inc. Announces Pacific Rim Commercialization Team in Australia and China
Date:5/9/2011

BETHLEHEM, Pa., QUEENSLAND, Australia and BEIJING, May 9, 2011 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today the formation of its Pacific Rim commercialization team to expand its presence in Australia and China.

Members of Saladax's Pacific Rim commercialization team include:

  • Yunying Li, Ph.D. (Saladax Biomedical, Inc.) – Dr. Li, Director of Market Development, Asia, with Saladax Biomedical, has held leadership roles in the Company since 2004.  Until 2010, she served as Research Group Leader, supervising product development efforts of the MyCare™ assay development group.  Prior to Saladax, Dr. Li was a senior research scientist at OraSure Technologies, Inc.  Dr. Li has relocated to Beijing where, utilizing her technical experience with the MyCare line and her cultural ties in China, she will lead the establishment of Saladax's commercial presence in this important market.  

  • Patrick Cook (Macarthur Cook Group Pty Ltd) – Mr. Cook is Principal at Macarthur Cook Group Pty Ltd, a privately held company in Queensland, Australia, which provides business development, education and training services.  Mr. Cook's extensive experience in the Australian diagnostic industry will help Saladax expand its sales and marketing efforts in Australia.  Mr. Cook serves as director and board member of IVD Australia Ltd., a leader in Australia's in vitro diagnostic industry.  He has worked with multiple international and local organizations including Roche Diagnostics, Quidel, Abbott Diagnostics and Royal Brisbane & Women's Hospital.

"With Dr. Li's extensive experience working with Saladax and Mr. Cook's significant knowledge and recognition in the diagnostics industry, we are confident we will successfully commercialize Saladax's assays in China and Australia," said Edward L. Erickson, president and CEO of Saladax.  

About Saladax Biomedical, Inc.

Saladax Biomedical develops and commercializes novel diagnostic assays to achieve the promise of personalized medicine through dose management and companion diagnostic products for existing and new therapeutics.  The Company's dose management technology enables physicians to optimize drug dosing to meet individual patient needs, leading to improved response and quality of life.  The Company's 15 MyCare™ dose management assays are comprised of proprietary, automated and cost-effective in vitro diagnostic tests, with a principal focus in oncology.  The first MyCare assay available is for one of the most common anticancer drugs, 5-fluorouracil (5-FU).  This assay is available in the United States from Myriad Genetics, sold by Saladax in Europe and will be distributed in Japan by FALCO biosystems.  Saladax also works with pharmaceutical companies to develop companion diagnostics to provide important clinical information to assist in developing and administering new and existing compounds.

Saladax Biomedical, Inc.
Adrienne Choma, Esq.
VP Marketing & Sales
achoma@saladax.com

Media Contact:
Tiberend Strategic Advisors, Inc.
212-827-0020
Andrew Mielach
amielach@tiberend.com
or
Farrell Denby
fdenby@tiberend.com


'/>"/>
SOURCE Saladax Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Saladax Biomedicals 5-FU Personalized Chemotherapy Management (PCM(R)) Assay CE Marked for Distribution in the EU
2. Binder Biomedical, Inc. Announces the Release of the X-GRAFT(TM) Interspinous Device, as Part of Their QUANTUM(TM) Line of Spinal Allograft Devices, Manufactured at the University of Miami Tissue Bank
3. BINDER BIOMEDICAL, INC. Announces Official Launch of the NEWTON™ Intervertebral Body Fusion Spinal Spacer System
4. Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical, Inc. Enter Strategic Partnership on Anti-Cancer Drugs Targeting Cancer Stem Cells
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... SEATTLE , Feb. 27, 2017  CTI BioPharma Corp. ... of Adam Craig , M.D., Ph.D., as President and ... Directors effective March 20, 2017. Dr. Craig succeeds Richard ... serve on the company,s Board of Directors.  Dr. Craig has ... development in both the US and Europe ...
(Date:2/27/2017)... -- Period October – December 2016 Revenues ... SEK -16.4 (-6.4) million Result after tax amounted to SEK ... dilution Cash flow from operating activities amounted to SEK -8.3 ... Period full year ... Operating result amounted to SEK -39.5 (-29.5) million ...
(Date:2/24/2017)... , Feb. 24, 2017  Today, exocad America ... labs have a new path to produce 510(K) ... Biodenta implant library integrated into exocad DentalCAD software. ... FDA compliant Good Manufacturing Processes (GMP,s) into their ... Biodenta, and complete an audit process. Then, dental labs ...
Breaking Medicine Technology:
(Date:2/27/2017)... RICHEY, Fla. (PRWEB) , ... February 27, 2017 , ... ... disorder, but concern for women who become dependent on opioid painkillers has fallen short. ... female patients, compared to a 237% increase in fatal overdoses in male populations.(1) , ...
(Date:2/27/2017)... , ... February 27, 2017 , ... Orange County ... a chronic inflammatory gum condition that occurs when the bacteria in plaque infect the ... referred to as a scaling and root planing or SRP, and can include surgical ...
(Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – ... disclosed that despite scientific studies, the Center for Disease Control ( CDC ) and ... . Kenneth B. Liegner, M.D. has compiled into a single volume a compelling ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair ... announce a new informational post on robotic hair transplantation. San Francisco residents may ... transplant and Follicular Unit Transplantation (FUT) can sound similar. Either treatment can be ...
(Date:2/26/2017)... ... February 25, 2017 , ... The February 13, 2017, assassination of ... concern over nerve agents and the deadly use of chemical weapons. Many questions exist ... how even small doses can be lethal. , Jay Jagannathan, M.D., of Michigan-based Jagannathan ...
Breaking Medicine News(10 mins):